Sharekhan

Alivus Life Sciences Ltd

Tue 27/01/2026,15:55:9 NSE: ALIVUS

₹ 888.20 4.70 (0.53%)
BUY NOW Buy Alivus Life Sciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Alivus Life Sciences Ltd

Tue 27/01/2026,16:1:0

Alivus Life Sciences Ltd

Tue 27/01/2026,15:55:9 | NSE : ALIVUS

₹ 888.204.70 (0.53%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 887.95

Previous Close

₹ 883.50

Volume

101281

Mkt Cap ( Rs. Cr)

₹10901.44

High

₹ 898.40

Low

₹ 867.25

52 Week High

₹ 1251.00

52 Week Low

₹ 819.00

Book Value Per Share

₹ 245.68

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alivus Life Sciences Ltd

Your Vote -

Buy

90.78%

Hold

7.28%

Sell

1.94%

90.78%

206 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

33%

Sell Order Quantity

67%

Bid Price

Qty

880.20

10

880.00

31

878.00

100

875.00

50

873.00

30

Bid Total

3653

Bid Price

Qty

888.15

24

888.00

9

894.00

30

898.00

100

899.00

10

Bid Total

7419

Option Chain

Analyzes market sentiment, predicts Alivus Life Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Jan 2026, 8:04PM Alivus Life Sciences Limited has informed the Exchange about Link of Recording of Earnings Call

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    22 Jan 2026, 8:00PM Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015,

  • Alivus Life Sciences Q3 net profit up 9.71% at Rs 150.26 cr

    22 Jan 2026, 3:20PM The company reported standalone net profit of Rs 150.26 crore for the quarter ended December 31, 2025 as compared to Rs 136.96 crore in the same perio

  • Alivus Life Sciences - Investor Presentation

    22 Jan 2026, 2:31PM Alivus Life Sciences Limited has informed the Exchange about Investor Presentation

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    22 Jan 2026, 2:28PM Please find enclosed herewith Investors Presentation - Q3 FY 25-26.

  • Alivus Life Sciences - Press Release

    22 Jan 2026, 2:23PM Alivus Life Sciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled ""Press Release on Unaudited Financial

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    22 Jan 2026, 2:22PM Enclosed please find herewith the Press Release on Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31,

  • Alivus Life Sciences - Unaudited Financial Results For The Third Quarter And Nine Months Ended 31 December, 2025.

    22 Jan 2026, 2:05PM Please find enclosed herewith Unaudited Financial Results for the Third Quarter and Nine Months ended 31st December, 2025.

  • Alivus Life Sciences - Outcome of Board Meeting

    22 Jan 2026, 1:50PM Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

  • Alivus Life Sciences - Board Meeting Outcome for Unaudited Financial Results For The Third Quarter And Nine Months Ended Dece

    22 Jan 2026, 1:50PM Pursuant to Regulations 30 and 33 of the SEBI (LODR), 2015, we wish to inform you that the Board at its meeting held today approved the unaudited Fina

  • Alivus Life Sciences - ESOP/ESOS/ESPS

    21 Jan 2026, 7:20PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of 55000 Shares.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    21 Jan 2026, 7:17PM Enclosed please find herewith intimation with respect to allotment of Equity Shares under the 'Employee Stock Option Scheme, 2021'.

  • Alivus Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    19 Jan 2026, 7:20PM As of December 2025, 74.91% is owned by Indian Promoters and 25.09% by Public. <p align=justify> Institutional holds 12.21% (Insurance Companies 0.27%

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    15 Jan 2026, 2:22PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 Jan 2026, 2:19PM Enclosed please find herewith the details of Earnings Call slated for Thursday, January 22, 2026 from 6:00 p.m. to 7:00 p.m. (IST), for your informati

  • Alivus Life Sciences - Trading Window

    14 Jan 2026, 5:16PM Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulati

  • Alivus Life Sciences - Board Meeting Intimation for The Unaudited Financial Results Of The Company For The Quarter And Nine M

    14 Jan 2026, 5:01PM Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/01/2026 ,inter alia, to consider

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Dec 2025, 6:00PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Dec 2025, 5:55PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Dec 2025, 5:22PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Dec 2025, 5:28PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 Dec 2025, 4:51PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Dec 2025, 4:36PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Dec 2025, 4:42PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Dec 2025, 5:01PM Alivus Life Sciences Limited has informed the Exchange about the Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Dec 2025, 5:07PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Dec 2025, 4:49PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Dec 2025, 5:00PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    27 Nov 2025, 8:59PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    27 Nov 2025, 8:53PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Nov 2025, 2:37PM Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst/Investor meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    14 Nov 2025, 2:30PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Nov 2025, 11:48AM Alivus Life Sciences Limited has informed the Exchange about Transcript

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 Nov 2025, 11:43AM Enclosed please find Transcript of Earnings Call.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    7 Nov 2025, 3:17PM Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015,

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Nov 2025, 3:08PM Alivus Life Sciences Limited has informed the Exchange about Weblink of Recording of Earnings Call Q2 FY2026.

  • Alivus Life Sciences - Investor Presentation

    6 Nov 2025, 7:28PM Alivus Life Sciences Limited has informed the Exchange about Investor Presentation

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    6 Nov 2025, 7:28PM Enclosing herewith Investor Presentation - Q2 FY 2025-26.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Nov 2025, 6:56PM Press Release - Q2 FY 2026 Financials

  • Alivus Life Sciences - Press Release

    6 Nov 2025, 6:55PM Alivus Life Sciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled ""Press Release - Q2 FY2026 Financial

  • Alivus Life Sciences Q2 net profit up 36.41% at Rs 130.03 cr

    6 Nov 2025, 6:51PM The company reported standalone net profit of Rs 130.03 crore for the quarter ended September 30, 2025 as compared to Rs 95.32 crore in the same perio

  • Alivus Life Sciences - Outcome of Board Meeting

    6 Nov 2025, 6:47PM Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

  • Alivus Life Sciences - Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2025

    6 Nov 2025, 6:44PM Please find enclosed Unaudited Financial Results for the Second quarter and Half Year ended September 30, 2025.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Oct 2025, 3:39PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    30 Oct 2025, 3:46PM Enclosed please find herewith the details of Earnings Call slated for Friday, November 7, 2025 from 8:30 a.m. to 9:30 a.m. (IST), for your information

  • Alivus Life Sciences - Trading Window

    29 Oct 2025, 5:44PM Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulati

  • Alivus Life Sciences - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter And Half Year

    29 Oct 2025, 5:36PM Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider

  • Glenmark Life Science

    11 Jul 2024 , 10:12AM Glenmark Pharmaceuticals' board of directors approved the sale of a 7.84% stake or 96,09,571 equity shares, in Glenmark Life Sciences Limited, as stated in its filing to the exchanges on Wednesday. The stake sale will be done through the stock exchanges via an offer for sale. (Negative)

  • Glenmark Life signs master supply agreement with a Japanese innovator pharma co

    19 Jan 2024 , 11:07AM Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese Innovator pharmaceutical Company

  • Glenmark Lifesciences

    31 Jul 2023 , 10:32AM The Nirma Group has emerged as the frontrunner to acquire Glenmark Life Sciences (GLS), an 82.84% subsidiary of Glenmark Pharmaceuticals. Strong positive for Glenmark Lifesciences

  • Glenmark Life Sciences report strong Q1 earnings

    21 Jul 2023 , 1:38PM Glenmark Life Sciences reported an 18% y-o-y rise in revenue to Rs 578.45 Cr in Q1FY24. It was driven by a 13.3% y-o-y increase in Generic API revenue to Rs. 504.2 Cr due to strong growth in regulated markets and steady growth in emerging markets while CDMO business recorded 91.0% growth y-o-y to Rs. 46.4 Cr due to healthy recovery in demand. As gross margins improved 385 bps y-o-y to 57% the gross profits increased 27% y-o-y to Rs. 330.41 Cr. This was driven by lower input costs and improved products mix. As a result, EBITDA increased 32% y-o-y to Rs. 193.16 Cr. while EBITDA margins remained stable y-o-y at 33% in Q1FY24. However, with 193% y-o-y rise in finance costs to Rs. 0.40 Cr the PAT increased at a slower but strong pace of 25% y-o-y to Rs. 135.45 Cr in Q1FY24. However, on a q-o-q basis, revenue and PAT declined at 7% each. Sales declined q-o-q due to high base effect. The management is hopeful of growth in the coming quarters on the back of capacity expansion and product pipeline as well as improved demand environment and supply situation. Positive for the stock.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Alivus Life Sciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 2817.372 2332.322 2138.207 2054.312 752.747
Liabilities 2817.372 2332.322 2138.207 2054.312 752.747
Equity 24.507 24.505 24.505 24.505 1.96
Gross Profit 682.584 674.246 642.293 616.06 591.074
Net Profit 485.627 470.888 466.961 418.724 351.581
Cash From Operating Activities 391.524 413.515 313.404 597.585 388.113
NPM(%) 20.34 20.62 21.6 19.72 18.64
Revenue 2386.884 2283.214 2161.22 2123.214 1885.165
Expenses 1704.3 1608.968 1518.927 1507.154 1294.091
ROE(%) 16.1 15.61 15.48 13.88 11.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
01 Sep 2025 5 250 0 1206
17 Oct 2023 22.5 1125 0 617.7
24 Mar 2023 21 1050 0 375.3
15 Sep 2022 10.5 525 0 489
22 Nov 2021 10.5 525 0 632.7

Peers

Other companies within the same industry or sector that are comparable to Alivus Life Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 674.80 -2.17 0.00 506.63 301.39 0.74
Lotus Eye Hospital and Institute Ltd 128.27 4.99 400.84 1846.09 3.55 0.00
Vaishali Pharma Ltd 8.19 -1.80 0.00 11581.12 3.13 0.00
Astec Lifesciences Ltd 577.30 1.38 0.00 1740.90 -604.77 0.00

Company Info

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore. 2025 -The Company name has changed from Glenmark Life Sciences Ltd to Alivus Life Sciences Ltd. -The Company Informed regarding Agreement and Power Supply Agreement between Alivus Life Sciences Ltd. and Torrent Urja 19 Private Ltd.

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore. 2025 -The Company name has changed from Glenmark Life Sciences Ltd to Alivus Life Sciences Ltd. -The Company Informed regarding Agreement and Power Supply Agreement between Alivus Life Sciences Ltd. and Torrent Urja 19 Private Ltd.

Read More

Parent Organisation

Alivus Life Sciences Ltd.

Founded

23/06/2011

Managing Director

Dr.Yasir Rawjee

NSE Symbol

ALIVUSEQ

FAQ

The current price of Alivus Life Sciences Ltd is ₹ 888.20.

The 52-week high for Alivus Life Sciences Ltd is ₹ 898.40 and the 52-week low is ₹ 867.25.

The market capitalization of Alivus Life Sciences Ltd is currently ₹ 10901.44. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alivus Life Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alivus Life Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alivus Life Sciences Ltd shares.

The CEO of Alivus Life Sciences Ltd is Dr.Yasir Rawjee, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT